Across TCGA pan-cancer cohorts, FBXO24 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of FBXO24’s most consistent transcriptional readouts.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where FBXO24 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types FBXO24 is over-expressed in tumor, although a few such as HNSC and LSCC show the opposite, repressed pattern.
HNSC, LSCC, and CCRCC are the cancer types where FBXO24 tumor–normal differential expression is most reproducible.